Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Array Expects To Have Phase III MEK Inhibitor All To Itself, Without Partner Novartis

This article was originally published in The Pink Sheet Daily

Executive Summary

Following Novartis’ oncology deal with GSK, which included another MEK inhibitor, Array anticipates getting the asset back for itself. Novartis would be obliged to continue supporting Phase III studies, Array says, as part of a pipeline update in second-quarter earnings call.

You may also be interested in...

Novartis/GSK Cancer Deal Gets FTC OK Based On Existing Divestments

Novartis’ transfer of Phase III BRAF and MEK inhibitors to partner Array BioPharma satisfies Federal Trade Commission’s anticompetitive concerns; no divestiture yet announced for GSK acquisition of Novartis [See Deal]vaccines.

Deal Watch: NASH Space Heats Up With Tobira/Regado Reverse-Merger

Roche buys out French biotech Trophos, with plans to continue developing its failed ALS candidate in spinal muscular atrophy. Meanwhile, the ramifications from last year’s complex Novartis/GSK tie-up continue, as Novartis transfers a Phase III BRAF inhibitor to Array a month after returning a MEK inhibitor to its former partner.

Novartis Thinks It Can Do Better With GSK’s Oncologics Than GSK Did

Novartis stresses the blockbuster potential, in its hands, of three products – Votrient, Tafinlar and Mekinist – that it is acquiring from GSK as part of its narrowed focus on innovative pharmaceuticals, eye care and generics, and the divestment of vaccines, OTCs and animal health.

Related Content


Related Companies

Related Deals

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts